President Trump blared about the “GREAT JOBS NUMBERS” from last week’s jobs report. But a deeper look at the data shows the U ...

Also, psilocybin may be headed for approval despite mildly anticlimactic remission rates, and Ocular’s wet AMD drug does .… ...

Payment rates for Medicare's ACCESS model, health insurers' use of AI, and more.

The FDA rejected a Disc Medicine therapy for a rare blood disorder, the first experimental drug to go through a new program ...

It’s officially been one year since Kennedy became the nation’s health secretary. He has made numerous promises and set many ...

You're reading the web edition of D.C. Diagnosis, STAT's guide to the ins and outs and oddities of health politics and policy ...

Facing shrinking profits and higher costs, health insurers are accelerating adoption of AI throughout their sprawling ...

Highly respected doctors on social media are endorsing questionable medical products — but they’re deepfakes, and they’re a ...

Compass Pathways on Tuesday disclosed results from two Phase 3 studies that support a potential approval of its psilocybin treatment for severe depression, but more detailed data are needed to ...

Ocular now plans to apply for FDA approval, but whether doctors and insurers will favor its new drug is an open question.

If IV opioids are in short supply, who gets pain relief — a teenager in agony with a crushed leg or an 80-year-old dying from cancer?

To understand what China's fast-developing drug industry might mean for global pharmaceutical companies, look no further than the market for GLP-1 drugs.